These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25156577)

  • 1. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis.
    Ruggiero S; Clavenna A; Reale L; Capuano A; Rossi F; Bonati M
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1578-90. PubMed ID: 25156577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis.
    Yu S; Shen S; Tao M
    J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):40-50. PubMed ID: 36944092
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
    Joseph A; Ayyagari R; Xie M; Cai S; Xie J; Huss M; Sikirica V
    Eur Child Adolesc Psychiatry; 2017 Aug; 26(8):875-897. PubMed ID: 28258319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Rizzo R; Martino D
    Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.
    Anand S; Tong H; Besag FMC; Chan EW; Cortese S; Wong ICK
    Paediatr Drugs; 2017 Jun; 19(3):235-250. PubMed ID: 28391425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
    McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF
    Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.
    Maneeton B; Maneeton N; Likhitsathian S; Suttajit S; Narkpongphun A; Srisurapanont M; Woottiluk P
    Drug Des Devel Ther; 2015; 9():1927-36. PubMed ID: 25897203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
    Capone GT; Brecher L; Bay M
    J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
    Hirota T; Schwartz S; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):153-73. PubMed ID: 24472251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.